Influenza Clinical Trial
Official title:
Phase 1 Single Dose Escalation/Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, And Pharmacokinetics of Ascending Doses of a MEK Inhibitor (ATR-002) Given for 7 Days in Healthy Subjects
This was a combination of a single ascending dose (SAD) study to evaluate the safety,
tolerability, and PK of 3 oral doses of a MEK inhibitor and a multiple ascending dose (MAD)
study of 3 oral doses of a MEK inhibitor.
Subjects were to be enrolled in 3 different cohorts in the SAD and 3 different cohorts in the
MAD and were to be randomly (blinded) allocated to active treatment or placebo (each cohort
consisted of 8 subjects receiving active treatment and 2 subjects receiving placebo).
Each subject in the SAD cohorts was to receive a single dose of the MEK inhibitor ATR-002
(PD0184264), with a starting dose of 100 mg ATR-002 or placebo:
- Cohort 1: 100 mg ATR-002 or placebo;
- Cohort 2: 100 mg + X mg ATR-002 or placebo;
- Cohort 3: 100 mg + X mg + Y mg ATR-002 or placebo. An additional cohort (Cohort 4) of 10
subjects (4:1 active vs placebo) could have been recruited into the SAD Part, if
appropriate.
Effectively, 4 cohorts were treated:
- Cohort 1: 100 mg ATR-002 or placebo;
- Cohort 2: 300 mg ATR-002 or placebo;
- Cohort 3: 600 mg ATR-002 or placebo;
- Cohort 4: 900 mg ATR-002 or placebo. Between each cohort, a blinded interim analysis of
PK, safety and tolerability had to be performed. The available data was evaluated by the
Investigator and sponsor in a Safety Review Committee (SRC) meeting.
Once a dose level was judged to be safe, the SRC determined the dose level for the next
cohort considering a maximal increment of 400 mg compared to the previous cohort, and the
next dose level could be administered to the next cohort.
The maximal dose level could not exceed 900 mg ATR-002. Each subject in the MAD cohorts was
to receive once daily (QD) doses (fasted) of the MEK inhibitor ATR-002 for 7 days, starting
with a dose of 100 mg ATR-002 or placebo QD.
- Cohort 5: 100 mg ATR-002 QD or placebo;
- Cohort 6: 100 mg + A mg ATR-002 QD or placebo;
- Cohort 7: 100 mg + A mg + B mg ATR-002 QD or placebo. An additional cohort (Cohort 8) of
10 subjects (4:1 active vs placebo) could be recruited into the MAD Part, if
appropriate.
Effectively, 3 cohorts were treated:
- Cohort 5: 100 mg ATR-002 QD or placebo;
- Cohort 6: 300 mg ATR-002 QD or placebo;
- Cohort 7: 600 mg ATR-002 QD or placebo. Between each cohort, a blinded interim analysis
of PK, safety and tolerability had to be performed. The available data was evaluated by
the Investigator and sponsor in a SRC meeting. Once a dose level was judged to be safe,
the SCR determined the dose level for the next cohort considering a maximal increment of
400 mg compared to the previous cohort, and the next dose level could be administered to
the next cohort.
The maximal dose level could not exceed 900 mg ATR-002. During the study, no repeated daily
dose could exceed the maximum single dose that has been shown to cause no safety concerns.
Subjects were resident on the ward from the day (late afternoon/evening) before dosing (Day
-1) until completion of procedures at 96h following their final dose of study medication.
They were to attend a follow up visit 28 days (± 2 days) following their final dose of study
medication.
Subjects with AEs that were ongoing at the end of the study were followed up as appropriate
until the AEs had resolved or stabilised, up to a maximum of 30 days after the last dose of
study drug.
Pharmacokinetics were determined predose 30 min, 1h, 2h, 4h, 8h, 12h, and 24h, postdose, and
predose on Day 2-4 in the SAD Part, and predose 30 min, 1h, 2h, 4h, 8h, 12h, and 24h, of Day
1 and Day 7, predose on Day 2-6 and 48h, 72h, and 96h post final dose of Day 7 in the MAD
Part. The 72h and 96h samples in both SAD and MAD were only to be analysed if deemed
informative based on the results of the 48h PK sample.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |